[HTML][HTML] Generic imatinib therapy among Jordanians: an observational assessment of efficacy and safety in routine clinical practice
A Awidi, S Abbasi, K Alrabi, KA Kheirallah - Clinical Lymphoma Myeloma …, 2017 - Elsevier
Introduction Generic imatinib therapy is being globally considered owing to cost
considerations. However, evidence of its efficacy and safety in Middle Eastern clinical …
considerations. However, evidence of its efficacy and safety in Middle Eastern clinical …
[HTML][HTML] Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
Background Generic formulations of imatinib mesylate have been introduced in Western
Europe since 2017 to treat patients with chronic myeloid leukemia (CML). However, results …
Europe since 2017 to treat patients with chronic myeloid leukemia (CML). However, results …
Cancer management by tyrosine kinase inhibitors: efficacy, limitation, and future strategies
VWT Ho, HY Tan, N Wang, Y Feng - Tyrosine Kinases as …, 2019 - books.google.com
Tyrosine kinase inhibitors are taking up an increasingly significant role in treating cancers.
There are different types of TKIs currently used in clinical settings. However, TKI-associated …
There are different types of TKIs currently used in clinical settings. However, TKI-associated …
A Critical Study of the Arguments for and against a Moratorium on Glivec
CR JEONG, J LEE, K KO - Korean Journal of Medical Ethics, 2017 - e-kjme.org
요약 글리벡 (Gleevec) 은 1999 년 스위스 제약회사인 노바티스사 (Novartis) 에 의해 개발된
만성골수성백혈 병 치료제이다. 노바티스사가 지난 2011 년부터 2016 년까지 한국에서 …
만성골수성백혈 병 치료제이다. 노바티스사가 지난 2011 년부터 2016 년까지 한국에서 …
[引用][C] Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
LA Passamonti, C Gambacorti-Passerini - 2020